Menarini Diagnostics was established in Florence in 1976 as a business division of the Italian Menarini Group (A. Menarini indus-trie Farmaceutiche Riunite) and is now represented throughout central Europe with its own branches. The drive behind the out-standing growth of recent years has been our 700 employees, of whom more than 75% are in an ongoing dialogue with the users of our products in their roles as marketing, distribution or custo-mer service staff. This high level of customer focus is an essential component of the Menarini business philosophy and brings our company motto ‘Menarini – The Human Touch of Technology’ to life. The German branch was established in 1998 and has been a division of Berlin-Chemie AG for organizational reasons since 2001. All business processes comply strictly with the requirements of the ISO 9002, ISO 13488 and EN 46002 standards.

The product range of A.Menarini Diagnostics includes high quality products for self-monitoring of blood glucose (glucoMen range) as well as supplying the following sectors in the traditional labora-tory market with fully automated analytical systems:

•Immunohistochemistryandin-situhybridization(Bond) •Autoimmunediagnostics(Zenit) •HbA1cdiagnostics •Urineanalysis(Sedimax)

Menarini focuses specifically not only on high product quality but also on improving internal laboratory processes in order to make a significant contribution to internal laboratory added value by in-creasing the level of automation.

coMpetencies

Diabetes diagnostics

•Self-monitoringofbloodglucose

•Continuousglucosemonitoring

•Customerservicecentrefor

diabetes

Laboratory diagnostics

•Immunohistochemistry

•Autoimmunediagnostics

•HbA1cdiagnostics

•Urinediagnostics

(incl. sedimentation analysis)

ßBond iii – Efficiency through speed GlucoMen®Gm: The latest blood glucose monitor from A.Menarini Diagnostics

A. Menarini Diagnostics DeutschlandDivision der Berlin-Chemie AGGlienicker Weg 12512489 BerlinGERMANYT +49 (0) 6707 30 00F +49 (0) 6707 30 20info@menarinidiagnostics.dewww.menarinidiagnostics.de

ATLAS Biolabs GmbH is a leading provider of complex analyses in the field of molecular genetics including microarray-based genomic services, targeted sequence capture, and next-gene-ration sequencing. The company performs genome-wide gene expression and SNP analyses, molecular karyotyping, mutation profiling and next-generation sequencing for academic institu-tions, pharmaceutical and biotechnological enterprises, clinicians and registered doctors. Expert data processing and bioinforma-tics capabilities ensure a high added value to the data genera-ted in its laboratories. More than 10 years of experience ensure high quality services to its customers. All production processes are subject to rigorous quality control according to DIN EN ISO 9001:2008. ATLAS Biolabs is also a partner for the design and manufacturing of in-vitro diagnostic medical devices according to EN ISO 13485:2003 + AC:2009. ATLAS Biolabs is a privately owned company (GmbH) founded by leading genome researchers as a spin-off from both the RZPD German Resource Center for Genome Research and the Cologne Center for Genomics (CCG). ATLAS Biolabs started its business operations in August 2007 in the centre of Berlin, Germany.

compeTencieS

NGS & Sequence Enrichment• Illumina, Life Technologies, Roche• Exome Enrichment (NimbleGen, Agilent), Custom Enrichment (RainDance)

Molecular Karyotyping• Agilent Array CGH, Affymetrix

SNP6 and CytoScan HD Array

Genotyping• Man, Mouse, and Production Animals • Custom Panels • Diagnostic Panels

Gene Expression• Affymetrix, Agilent, Illumina

Sample Preparation• DNA, RNA

Bioinformatics• Microarray Design• Data Analysis• Software Engineering

ATLAS Biolabs GmbHFriedrichstraße 14710117 BerlinGERMANYT +49 (0) 30 319 89 66-0F +49 (0) 30 319 89 66-19customer-support@atlas-biolabs.dewww.atlas-biolabs.de

ß Mass spectrometer at ATLAS Biolabs GmbH, a highly flexible technology platform for SNP genotyping and DNA methylation studies

Next-generation sequencing can be offered from all major vendors by ATLAS Biolabs through its partners.

Attomol is a biotechnology company to the south of Berlin, foun-ded in 1997. We develop, produce and sell medical diagnostic products for the areas of molecular genetics, infectiology and au-toimmune diagnostics.

Quicktype proof of mutations, such as Factor V or lactose intole-rance, are based on allele-specific PCR with an integrated special hybridization, their assessment through gel electrophoresis or au-tomated with capillary electrophoresis.

LoopTag is a novel special system for real-time PCR for the semi-quantitative detection of genome fragments of human pathogen bacteria such as Borrelia burgdorferi, Mycobacterium tuberculosis, Bordetella and viruses as well as internal amplification controls.

DNS-LINA are direct sources of PCR pathogen verification, whe-rein pathogen-specific gene fragments as well as an internal am-plification check are multiplied and are verified through reverse hybridization on a test strip.

Antibody-LINA are strip tests for the determination of auto-anti-bodies against gangliosides and phospholipids.

Bead assays are multi-parameter proofs in the microtiter plate for-mat with the use of immobilized, fluorescent-coded bead popula-tions for the detection of antibodies in patient serums.

compeTeNcIeS

Molecular diagnostics

• Real-time PCR

• Multiplex proof

• Pathogen proof

• Gene tests

Immune diagnostics

• Auto-antibodies

• Multiplex proof

• Bead assay

• Strip tests

R&D areas of focus are bead assays

for the real-time PCR verification of

nucleic acids and for the detection

of antibodies.

Attomol GmbHSchulweg 603205 BronkowGERMANYT +49 (0) 35329 5906 -0F +49 (0) 35329 5906 -19info@attomol.dewww.attomol.de

ß Antibody bead assay: Antibodies against 11 nuclear antigens can be verified using fluores- cent-coded beads.  

BAM Federal Institute for Materials Research and Testing uses its competences to promote safety in technology and chemistry through research & development, testing, analysis, approval and certifi cation as well as consultation, information and advice. It co-operates in the development of regulations, standards and metro-logical issues with national and international bodies. Furthermore reference materials and reference methods are being developed, especially in analytical chemistry. BAM is a partner of academic and industrial research and performs knowledge and technology transfer with the aim to foster German economy.

Division 1.8 Immunoanalytics in Department 1 Analytical Che-mistry; Reference Materials is dedicated to antibody-based ana-lytical methods. We develop and validate immunoassays and other test formats. In the sense of an enabling strategy we divulge tech-nology and knowledge via publications, in-house trainings and by passing on standardized reagents. We work on metrological pro-blems, questions of quality assurance and take part in interlabora-tory comparisons.Application areas of our methods are Environmental Monitoring, Drug Screening and Clinical in vitro Diagnostics.

COMPETENCIES

Antibody Development

• Mono- and polyclonal antibodies, esp. against low-molecular analytes• Concepts for coupleable derivati- ves (haptens)• Hapten & immunogen synthesis and characterization • Techniques: LC-MS/MS, HR-MS, MALDI-TOF/MS, fl uorescence, NMR, x-ray structure analysis• Labeling, e.g. with enzymes, fl uo- rophores, nanoparticles

• Hybridoma screening

Development of Immunoassays

• Enzyme-based: ELISA direct/ indi- rect, CLEIA• Fluorescence-based: FIA, FPIA• Quick test formats: point-of-care, bedside & on-site testing• Comparison of assay formats, refe- rence analysis, validation concepts• Compilation of SOPs• Storage, testing and sale of immu- noreagents

BAM Federal Institute for Materials Research and TestingDept. 1 – Division ImmunoanalyticsRichard-Willstaetter-Str. 1112489 BerlinGERMANYT +49 (0) 30 8104 115-1F +49 (0) 30 8104 115-7rudolf.schneider@bam.dewww.bam.de

Mission Statement: Antibodies as analytical tools

ß Numerous factors infl uence accuracy, precision, sensitivity, and selectivity of immunoassays, e.g. temperature and rea- ding mode.

BioTeZ, founded in 1992, is based at the Biotechnologie Campus Berlin-Buch. The company’s business fields encompass immuno-assays, oligonucleotides, research and services.

We offer our clients:

ImmunoaffInITy ChromaTography• own technology for production of IAC

• a million times proven quality mostly for mycotoxin and vitamin analyses

CusTomIZed olIgonuCleoTId synThesIs• modified and unmodified DNA and RNA oligos

• oligos in microtiter plates

• siRNA oligos

• chimeric oligos

ImmoBIlIZaTIon of BIoTInylaTed moleCulesstreptavidin-Biotin systems

• optimal to bind and to analyze for example peptides, PCR fragments or haptens

• Streptavidin-coated microtiter plates or Polystrept R for lateral flow diagnostics.

Benefit from the advantages: high signal noise relation, low NSB, long shelf

time, savings in materials and high cost savings - especially for flow tests

CompanIon dIagnosTICs WITh BIologICs neW recoveryelIsa® Tests

• patented diagnostic to monitor the specific effects of biologics/

therapeutic antibodies (TAB)

• measuring patient samples defiant of TAB

• one-step determination of free antigen and its neutralization rate, level of

TAB and the recovery curve (model of specific antigen-antibody interaction).

CompeTenCIes

Immunoaffinity Chromatography

• production of customized IAC

• coupling of various ligands

Oligonucleotid Synthesis

• DNA/RNA incl. modifications

Immobilization with Streptavidin

Systems

• different surfaces

• coated microplates

• improving flow tests with

Polystrept R

ELISA Development and

Biotechnological Services

• e.g. labeling, conjugates,

purification

Companion Diagnostics

• recoveryELISA® during therapy

with biologics

BioTeZ Berlin-Buch GmbHRobert-Rössle-Str. 1013125 BerlinGERMANYT +49 (0) 30 94 89 213-0F +49 (0) 30 94 94 509info@biotez.dewww.biotez.de

ß recoveryELISA test kit free IgE/Omalizumab for measuring 7 serum samples

BioTOP Berlin-Brandenburg is the central contact and coordina-tion office for all issues concerning biotechnology in the German Capital Region. The region stands for its unique research and clini-cal landscape as well as the ability to closely link and network the major players in the life sciences and healthcare cluster. The many technology parks and networks in the various branches of modern biotechnology create the excellent infrastructure and technologi-cal support that characterize the Berlin-Brandenburg biotech area.

As a network node BioTOP offers support and information con-cerning all questions in biotechnology – quickly and outcome-oriented. It is the objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to extend the region’s leading position in biotechnology and life sciences worldwide.The target groups are universities, research institutes, start-ups, SMEs, service providers, investors and politicians.

BioTOP is a joint initiative of the federal states of Berlin and Bran-denburg in the TSB Innovationsagentur Berlin GmbH and part of the regional healthcare industries cluster HealthCapital.

cOmPeTencies

Focal Points

• Biomedicine and Diagnostics• Therapeutics and Regenerative Medicine

• Industrial Biotechnology

Our Services

• Technology transfer between science and industry • Initiation and support of networks • Support for technology-oriented start-ups • Funding support for innovative project concepts • Providing and presenting bio- technology information • Building and coordinating of scientific and interdisciplinary networks • Establishing contacts between experts from all disciplines • Organization of events and seminars• Public Relations work for the biotechnology region

BioTOP Berlin-BrandenburgFasanenstr. 85 10623 BerlinGERMANYT +49 (0) 30 31 86 22-0F +49 (0) 30 31 86 22-22biotop@biotop.dewww.biotop.de

The company’s history dates back to 1975 when the very first Ger-man biosensor research group started at the Berlin Academy of Sciences. Today BST is market leader in multi-way biosensors in Europe and an international operating company.

With the GLUKOMETERPRO BST has developed a unique device for professional glucose determination in the POCT market that befo-re this day could only be found in a laboratory. The BST multi-way glucose biosensor which is the bioanalytical basis of the GLUKO-METERPRO is essential for bringing lab quality out of the lab into the POCT area. Only 1 multi-way glucose sensor is necessary for 1000 samples within 4 weeks, while 1000 disposable sensors are neces-sary for 1000 samples. It is this professional technique in particular that allows lab quality within the POCT area.

The LABTREND is a flexible laboratory analyzer for either glucose or lactate and for laboratories of any scale. This analyzer works with interchangeable sample racks, meaning that one up to end-less samples can be measured (in succession) in the same analyzer. Thus the analyzer can be adjusted easily to the daily demand of hospitals of any scale. Like GLUKOMETERPRO the LABTREND is also based on BST’s multi-way biosensors. You can find more information about us under www.bst-biosensor.com.

compeTencieS

Conception, development and

production of

•Multi-waybiosensorfrom

nmol/l to mmol/l

•Glucoselaboratoryanalyzer

•GlucosePOCTanalyzer

•Consumables

•Immobilizationofbiological

recognition elements

BST Bio Sensor Technology GmbHBuchholzer Straße 55-6113156 Berlin GERMANYT +49 (0) 30 767 67 31-0F +49 (0) 30 767 67 31-28info@bst-biosensor.dewww.bst-biosensor.de

ß BST-biosensor for application in medicine, food & environmental diagnosticsß GLUKOMETERPRO (POCT): worldwide unique with multi-way biosensor

Since 1999, CellTrend GmbH has successfully offered its products and services in the areas of ‘cell culture’ test systems and ‘immu-noassays’. The area of individual therapy optimization was esta-blished at Zentrum für molekulare Onkologie GmbH (Centre of Molecular Oncology).

CellTrend develops and produces immunoassays for diagnostics and research. Novel treatment concepts in kidney transplantation and scleroderma are possible using new markers in autoantibody diagnostics (angiotensin II-receptor 1, endothelin receptor A). In addition, CellTrend is an experienced partner for development projects and studies as an order-based lab.

As a manufacturer of diagnostics and research products we main-tain a high-quality standard and act as a partner to pharmaceutical companies, clinics and research institutions. To implement and do-cument this claim during daily work, CellTrend provides a certified quality management system according to the standards ISO 9001, ISO 13485, ISO 13485 CMDR (Canada Medical Devices Regulati-on) and GMP.

CompeTenCies

Cell culture test systems

•Bioassays

•In-vitroassays

•Pre-clinic&qualitycontrol

•Primarycells&celllines

IMMUNOASSAYS

•Orderdevelopment

•Orderproduction(alsoOEM)

•Ourownkitsfordiagnosticsand

research

•Biomarkerdevelopment

•Orderanalytics(labservice)

•Primarycells&celllines

CellTrend GmbHImBiotechnologiepark,TGZ214943 LuckenwaldeGERMANYT+49(0)3371681-290F+49(0)3371681-312info@celltrend.dewww.celltrend.dewww.molekulare-onkologie.eu

ß At the CellTrend cell culture lab CellTrendELISAKit

As a collaboration between the Charité organization and the Max-Delbrück Center of Molecular Medicine (MDC), the Experimental and Clinical Research Center (ECRC) represents a combination of basic and clinical research. Here we develop new approaches for diagnosis, prevention and treatment of different indications and apply them on patients. With a station for clinical research, col-lege out-patient departments, a unit for an ultra-high field MR and research labs, ECRC offers an innovative environment for patient-oriented research.

The basic research of the stock company Müller/Dechend focuses on end organ damages due to hypertension which are characte-rized by and are based on their therapeutic traits. In the animal physiology area, well characterized animal models for hyperten-sion, pre-eclampsia and metabolic syndrome are applied in phar-maceutical studies. In the area of pre-eclampsia, there is close con-tact with a Norwegian biobank.

The Franz-Volhard Centre of Clinical Research (CRC) specializes in the area of development and sampling of new diagnostic and therapeutic approaches with a focus on the area of metabolic syn-drome. In addition to diagnostics and therapy studies, we have many years of experience in the professional implementation of pharmaceutical tests of the phases IIa to IV. The studies are per-formed reliably and in a timely manner according to established standards (GCP directives/AMG).

CoMpEtEnCiEs

Basic Research

•Cellculture-basedassays

•Expressionanalyses

•Confocalmicroscopy

•Animal models (hypertension,

pre-eclampsia, metabolic syndrome)

•Animalphysiologytests

•Pre-eclampsiabiobank

Clinical Research

•Studydesign,studyplanning

•Creationofstudydocuments

•Regulatoryandethicalconcerns

•Implementationofstudies

•Preparation&publication

•Consultationservices

ECRC, Lindenberger Weg 8013125 Berlin, GERMANy

Dr. Florian Herse (Basic Research)T +49 (0) 30 450 54 04 34F +49 (0) 30 450 54 09 00florian.herse@charite.dewww.mdc-berlin.de/de/ecrc

Dr. Heidrun Mehling (Clinical Research)T +49 (0) 30 450 54 04 75F +49 (0) 30 450 54 09 20heidrun.mehling@charite.dewww.charite-buch.de/crc

The translative success, as practiced at ECRC, is also the key to success in biomarker development.

PHILOSOPHY

As a law practice specializing in medical law we have offered compe-tence and experience since 1997. We guarantee that you can place your personal and entrepreneurial decisions on a reliable legal basis. Therefore, it is appropriate for us to address major issues along with you. Not only do we show you your legal limits but also ways that can help you achieve your goals. Sustainable negotiations, organization and processing are our strength.

COMPETENCE

We provide consultation in all areas of medical law. Our clients are, among other things, domestic and foreign pharmaceutical and medical product manufacturers and suppliers of health services. Our strength lies in consultations in the areas of social law and health care policy. Particularly in the area of pharmaceutical law, we combine intensive expertise with medical know-how.

AREAS OF FOCUS

• Market access and integration of products into the health care system • Cost reimbursement of medicines and medical products, particularly companion diagnostics • Pharmaceutical regress, pharmaceutical sales• Due diligence• Law on advertising in the Health Care System (HWG) and business compliance• Physician and hospital law

COMPETENCIES

Consultation in all areas of medical

law, including:

• Medical product law

• Pharmaceutical law

• Telemedicine

• Statutory health insurance

• Pharmaceutical law

• Medicine and medical aids law

• Hospital law

• Nursing insurance

• Physician‘s law

• Anti-trust law

• Commercial legal protection

• Data protection law

• Public procurement law

Dierks+Bohle RechtsanwälteWalter-Benjamin-Platz 610629 BerlinGERMANYT +49 (0) 30 32 77 87-0F +49 (0) 30 32 77 87-77offi ce@db-law.dewww.db-law.de

ß Prof. Christian Dierks (Dr. med. Dr. iur.) is a professor at the Charité Centre of Human Health Care Science (Charitécentrum für Human- und Gesundheitswissenschaften) and General Secretary of the German Association of Medical Law.

DMB-Diagnostics was founded by Dr. Martin Burow following many years in leading positions in international sales & marketing & distribution of diagnostics at Brahms AG (part of Thermo Fisher). DMB supports companies through project management, interim management and consulting in the field of medical diagnostics, medical devices and biotechnology. This comprises companies which want to take first steps to develop their Asian Pacific activi-ties and vice versa Asian companies trying to enter the European medical markets.DMB collaborates with experienced country specialists from the Asian Pacific region and local distributors in Japan, Korea, China, Taiwan, India, South East Asia and Australia.

OUR SERVICE COMPRISES FOLLOWING TASKS:

• Individual marketing & sales strategy for Asia and Australia, tailored for each single country and product

• Identification of suitable distributors and co-operation partners

• Registration and reimbursement application in collaboration with distributors

• Product and project management for your business in Asia ranging from market research, registration to sales & marketing

• Organization of for example roadshows, product and technical trainings, regional sales meetings, conference participation, and hospital visits

COMPETENCIES

Consulting for

• Japan, Korea, China, South East

Asia, India, Australia, others on

request

• Specific characteristics of the

Asian medical markets

• Reimbursement and price listings

for medical devices

• Strategic market development

Distribution

• Distributor search and evaluation

• Organization of clinical trials for

diagnostics

• Support for Merger & Acquisition

• Registration of medical devices /

diagnostics

• Product & project management

• Interim management

DMB-DiagnosticsGlienicker Straße 70a14612 Falkensee bei BerlinGERMANYT +49 (0) 3322 42 48 99 7F +49 (0) 3322 42 48 72 9info@dmb-diagnostics.de www.dmb-diagnostics.de

Special competence in the field of sepsis, prenatal, cancer and thyroid diagnostics

ß Dr. Martin Burow Founder and owner of DMB-Diagnostics

About Epiontis

using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service for research and clinical studies, as well as customized development of epigenetic assays. since our foundation in 2003 our laboratories are located at the Adlershof technology park in berlin, Germany.

our businEss

Epiontis‘ epigenetic assay format allows to identify and quantify any cell type with accuracy and technical ease. our assays are used as a quality control tool to ensure purity of cellular samples in e.g. Cell therapy and regenerative Medicine.

For applications where monitoring of specific cell types in the hu-man body is required, we offer a portfolio of established assays for immune cells. Examples include diagnostic assays for regulatory t cells (treg) and tumor infiltrating lymphocytes, with assays for den-dritic and antigen presenting cells under development.

Epiontis‘ assays perform well with a very low sample volume and have minimal restrictions on sample handling while allowing free-zing and long-term sample storage. our assays are used for clini-cal studies in many indications including cancer, infectious, and autoimmune disease. understanding the individual differences in immune cell numbers in those diseases will be a key to the deve-lopment of patient-centered, personalized therapies of the future.

compEtEnciEs

Marker Discovery and

Assay Development

•Identificationofepigenetic

markers specific for individual

cell types

•Validationofmarkers

•Developmentofquantitative

real-time pCr assays

immunomonitoring service

•QuantitationofTreg,overall

t cells and nK cells in clinical

samples

•Wholebloodandtissuesamples,

fresh, frozen, FFpE can be tested

•Anyanti-coagulantwillwork

•Idealforretrospectivestudies

and samples from clinical trials

ßthe epigenetically active CD3 gene (red) is a marker for overall t cells. the marker copy number directly translates into cell counts.

Epiontis GmbHrudower Chaussee 2912489 berlin AdlershofGErMAnYt +49 (0) 30 639 20 34 74F +49 (0) 30 639 20 34 76hoffmueller@epiontis.comwww.epiontis.com

The Potsdam-Golm branch of the Fraunhofer Institute for Bio-medical Engineering IBMT focuses on the development of high-ly innovative solutions for biomedicine and modern diagnostics. Both highly motivated scientists from different disciplines and ex-cellently trained engineers pool their expertise at the IBMT and

– together with state-of-the-art equipment – provide the basis for successful research and development projects.

A current example is the development of a modular platform for in-vitro Diagnostics (ivD). This platform is characterized by a high degree of fl exibility and modularity and offers the possibility for ra-pid diagnostics at the point-of-care, e.g. in intensive care or emer-gency medicine. Another example is the current development of novel molecular biosensors which enable identifying a disease directly on-site in the medical practice. This project is therefore called “Lab in a Hankie – Impulse Centre for Integrated Bioana-lysis“.

The range of research activities and services of the institute is com-pleted by extensive expertise in the fi elds of Cellular Biotechno-logy, Nanobiotechnology, Meta-Biobanking, Functional Surfaces and Molecular Bioanalytics – making the IBMT a competent part-ner for both the DiagnostikNetBB and industrial customers.

We look forward to receiving your call!

COMPETENCIES

Molecular Bioanalytics

• Biosensors

• Microarray & Biochip Technology

• Laboratory Automation / Systems

Integration

Nanobiotechnology

• Technical Molecular Biology

• Biomolecular Nanostructures

• Cell Programming and

Bioinformatics

• Biomimetic Functional Materials

• Biomarker Identifi cation &

Validation

• Biofunctional Surfaces

Cellular Biotechnology

• Lab-On-Chip Technology

• Miniaturized Cell Assays

• Microfl uidics

• Cell-Free Protein Synthesis

• Extremophile Research &

Biobank CCCryo

Meta-Biobanking

Fraunhofer Institute for Biomedical Engineering IBMTBranch Potsdam-GolmAm Mühlenberg 1314476 PotsdamGERMANYT +49 (0) 331 58187 01F +49 (0) 331 58187 99info-potsdam@ibmt.fraunhofer.de www.ibmt.fraunhofer.de

ß Left: Lab-On-Chip Device for the Stimulation and Analysis of Single Cells (©Jochen Zick)

ß Right: Modular ivD-Platform for Multipara- meter Analysis of Biological Samples (©Jochen Zick)

Founded in 2002, GA Generic Assays GmbH is a privately owned company manufacturing and distributing diagnostic test kits focu-sing on autoimmune diseases. GA is certified under DIN EN ISO 9001and DIN EN ISO 13485. The company‘s aim is to provide high quality diagnostic tools to meet the ever-growing demand for af-fordable tests. Located in Dahlewitz, close to the German capital Berlin, GA colla-borates with clinical research departments situated in universities all around Germany.

Our highly qualified staff is happy to give advice and support to customers if required. In Germany our products are marketed by our own sales force. In other countries, GA‘s products are marke-ted through competent national distributors.The product range, which focuses on innovative autoimmune diag-nostics, is constantly expanding and our ambitious plan for the fu-ture is the development of new parameters and new technologies for the diagnostic market.

competencies

Methods

•Immunofluorescence

•ELISA

•Latex/Quicktest

•LINE/Dot

•Blot

•PCR

Disease Groups

•Systemicinflammatoryrheumatic

disease

•Organspecificautoimmune

disease

•Infectiousdisease

•Pathogendiagnosis

•Mutationassay

•Drugtest

ßOffice building of GA

GA Generic Assays GmbHLudwig-Erhard-Ring315827Dahlewitz/BerlinGERMANYT +49 (0) 33708 92 86-0F +49 (0) 33708 92 86-50info@genericassays.comwww.genericassays.com

Dr. Frieda Gerdes is founder and senior consultant for Gerdes Healthcare Communication. Prior to founding her own company Frieda Gerdes held senior positions specializing in inter-national marketing and sales of IVD and life science products, e. g. for Epigenomics, Agendia and Life Technologies (formerly Applied Biosystems). Gerdes Healthcare Communication supports compa-nies with strategic consultancy, project management, education and interims management in in-vitro diagnostics, medical devices, treatments and services. The company specifically concentrates on young, research-driven businesses, whose focus is on developing innovative products they wish to introduce into European markets in a proficient and effective way.

CompetenCies

Strategic and Operational

Marketing

• Quickly and efficiently filling gaps

in client expertise and resources

• Identifying potential pitfalls in

product launches and the

building of new markets

• Expertise in achieving a

competitive advantage through

target group-oriented, clear

communication

• Tailored marketing planning and

focusing resource utilization

• Customized expertise and skills

to support your organization for

sustainable improvement

Gerdes Healthcare CommunicationZehdenicker Straße 8a10119 BerlinGERMANYT +49 (0) 30 32 66 9070M +49 (0) 173 800 51 32info@gerdes-hc.comwww.gerdes-hc.com

ß Dr. Frieda Gerdes Founder and Senior Consultant

We offer:

strateGiC marketinG

• Consultancy and Interims Management

• Strategic Marketing Planning• Marketing Requirement Documents

marketinG CommuniCation

• Key Messages and Feature- Benefit-Value Analysis

• Copy Writing• Conception and Execution of the Sales Tool Box

• PR and Media Strategy and Execution

• Online Marketing• Observance of Legal Regulations (e. g. German HWG and EU guidelines)

produCt manaGement• Analysis and Assessment of Product Portfolio

• Customer-oriented Product Development and Customer Integration

• Marketing Mix• Pricing Disposition and Strategy• Budget Calculation

market researCH

• Online Surveys • Print and Telefone Surveys• Focus Groups• Advisory Board Discussions• Empirical Analysis

traininG and events

• Preparation and Execution of Trainings and Presentations

• Event Promotion• Press Conferences • Booth Conception

Our principles• The results belong to the patients.• We are committed to actively integrated care.• Our focus is on special diagnostics without neglecting basic diagnostics.

• Networked expertise – fast and reliable.

The hospital laborverbund Brandenburg-Berlin GmbH is located in Berlin and employs about 100 staff at 5 sites in both Berlin and Brandenburg. Each year we perform more than 4 million tests using a total of 2000 different analytical procedures. Our aim is to achieve cost-effective, fast and high-quality analysis above and beyond the boundaries of care. With our newest laboratory site in Hennigsdorf we are now loca-ted in one of the most modern technology sites in the region – in keeping with our principle ‘Networked expertise – fast and reliab-le’. We form part of a network of innovative life science industrial companies and medical service providers. Our software-controlled supply logistics specifically for hospitals and cooperatives of pri-vate doctors enable us to bundle standardized procedures and expertise. The laboratory association also looks after the require-ments of point-of-care diagnostics.

We want to continue to competitively care for and supply the regi-on going into the future.

cOmpetencies

Expertise in all working areas

• General and specific clinical

chemistry

• Transfusion medicine

• Microbiology and molecular

diagnostics

• Autoimmune diagnostics

• Water testing in accordance with

TVO

• CSF diagnostics

Services

• Round-the-clock advice for

medical professionals

• Development of laboratory

medicine treatment concepts

including POCT

• Quality management

• Hygiene and infection management

• Borreliosis advice

• Clinical research and biobanking

• Continued education and

professional development

hospital Laborverbund Brandenburg-Berlin GmbHAm Kleinen Wannsee 5a14109 BerlinGERMANYT +49 (0) 800 5600 950-256F +49 (0) 800 5600 950-250mail@hospital-laborverbund.dewww.hospital-laborverbund.de

ß PCR analyses belong to the lab’s standard repertoire.

ICI – immunochemical intelligence gmbh – is dedicated to the de-velopment and production of innovative immunoassay components and kits for research use. The team of ICI has extensive experience in the development of immunoassay systems and is professional skilled. Their experience and know-how enables customers to achieve a fast and more cost-effective route to a ready-to-use product. Several members of staff have expertise in the IVD market and are also well acquainted to GMP regulations. This scientific competence makes an impact and is re-flected in our work which is compliant to ISO 9001.So ICI can provide the highest quality R&D services to support and accelerate their partners’ product development efforts. With profes-sionalism, innovation and objectivity ICI helps their customers to ad-vance their projects in a timely and cost-effective manner.

ICI offers followIng servICes: • Custom Immunoassay Development Services• Sample Analysis

ICI´s goal is to provide individual solutions, exactly tailored to the client’s needs and to create lasting relationships by providing out-standing services and high-quality products to demanding clients. Their quality control systems and state-of-the-art facilities will ensure reproducibility of their custom assays in your lab.

CompetenCIes

Service

• Custom assays

• Immunoassay development

• Sample analysis

• Cost-effective

• Time-saving

Team and Company

• Extensive experience

• Expertise in the IVD market

• Well acquainted to GMP regulations

• State-of-the-art facilities

• ISO 9001 certified

ICI immunochemical intelligence gmbhOranienstr. 2410999 BerlinGERMANYT +49 (0) 30 61 20 17-65F +49 (0) 30 61 20 17-88contact@ici-diagnostics.comwww.ici-diagnostics.com

ß precision and recovery – the most important attributes of our products

The Berlin Institute of Laboratory Medicine (IFLB) is an indepen-dent specialist medical lab in central Berlin which has offered lab services for human physicians, dentists, hospitals and retirement homes for over 20 years. Our practice collaborates closely with lab communities in Berlin and Mecklenburg-West Pomerania and with renowned partners. In this way, we are able to perform the ba-sic clinical/chemical and hematological diagnostics near you and also a wide range of cutting-edge, highly specified diagnostics. In particular, we have set ourselves apart in the areas of endocrinolo-gy and molecular pathogen diagnostics, for example in HIV resis-tance diagnostics.Our many years of lab experience and the short transport rou-tes for sample materials are the most important requirements to achieve quick and high-quality analytics. In addition, the Berlin In-stitute of Laboratory Medicine is obligated to perform quality ma-nagement according to the requirements of the standard DIN EN 15189. IFLB has DAR accreditation with the accreditation number DAP-ML-4004.99.IFLB‘s work is performed by 80 employees. Doctors, natural scien-tists and medical/technical personnel contribute their competence and qualifications in equal measure and assume the responsibility for the management and function of the lab areas.

coMpetencIes

Lab diagnostics•Fulldiagnosticoffering•Personalconsultation•Same-daycompletionoftasks because there is no long sample transport•Molecularbiologypathogen diagnostics•Quickandcompetentmicrobio-

logical findings

Service

•Freesupplyofdisposalmaterials•Electroniclabrequests(orderentry)•Flexibledriverservice•Laboratorycommunity(private andcashpoint)•Advancededucation•Supportforpre-analysisandbud- get calculation

IFLB offers collegial consultation and innovative diag-nostics in the Berlin and Mecklenburg-West Pomerania region taking the individual needs of its senders.

Institut für LaboratoriumsmedizinBerlin(IFLB)Windscheidstraße 1810627 BerlinGERMANYT+49(0)327903-0F+49(0)327903-90info@iflb.dewww.iflb.de

As a Leibniz Institute IHP works primarily on long-term, strategic research tasks. Here it can combine fundamental research with applied research. The Institute researches and develops silicon-based systems, highest-frequency circuits and technologies for wi-reless and broadband communication and verifies them through prototypes.

The research by IHP is focusing more and more on the implemen-tation of innovations for different areas of societal life. Numerous research projects entail goals which involve novel solutions in the areas of communication, mobility, security, energy and medicine/biotechnology.

The work by IHP is structured into four coordinated research programs:

• Wirelesssystemsandapplications• High-frequencycircuits• Technologyplatformforwirelessandbroadbandcommunication• Materialsformicro-andnanoelectronics

This structure allows for the implementation of vertically optimized solutions for new application areas. IHP pursues a „More thanMoore“strategy–meaningthatthegoalistointegratemoduleswithadditionalfunctionalityintotheBiCMOSbasictechnology.

comPetencIes

•Identificationofnewmaterial

systems for future, silicon-based

microtechnologies

•Modularexpansionofstandard

CMOStechnology

•MPWandprototypingservice

•Designofanalogueradiocircuits

for frequencies up to 124 GHz

•Developmentofsolutionsfor

context-sensitivewireless

applications

•Wirelesslocalandbodyarea

networking

•Digitalandmixedradiosignal

design

• Processor design and development

•Electricalmetrologyincluding

HF tests

•Componentphysicsandmodeling

IHP GmbHInnovations for High Performance Microelectronics/InstitutfürInnovativeMikroelektronikIm Technologiepark 2515236Frankfurt(Oder)GERMANYT+49(0)3355625-0F+49(0)3355625-300ihp@ihp-microelectronics.com www.ihp-microelectronics.com

InstItute CardIaC dIagnostICs and therapy (IKdt)

IKdt is a worldwide leading laboratory in differential diagnostics of viral infections and inflammation of heart muscle tissue fol-lowing the international recommendations. Three key diagnostic topics will be covered for routine diagnostics:

•Histology

• Immunohistochemistry

•Molecular Virology

IKDT is the only cardiological laboratory performing molecular di-agnostics of endomyocardial biopsies in Germany which is accre-dited by the College of American Pathologists (CAP) according to FDA guidelines. Customers for our biopsy diagnostics are hospi-tal-affiliated institutions or private doctor offices.

As one of the first service providers in Europe IKDT’s platform Innovative diagnostics lab offers customers prompt access to three innovative research technologies:

• Taqman Low Density Arrays (Lifetechnologies) for gene expression studies or microRNA profiling by Low Density Arrays or Open Arrays• Bead-based Luminex technology for multiplex measurement of cyto- kines, phosphoproteins, immunological profiles and microRNA sets • GeXPtechnology(BeckmanCoulter)formultiplexgeneexpressi- on analysis by fragment length discrimination.

CompetenCIes

• Differentialdiagnosticsofendo- myocardial biopsies• Histologyofheartmuscletissue• Immunohistochemistryincl. digital image analysis• Moleculardiagnosticsof cardiotropic infectious agents• Geneexpression&microRNA profiling in myocardial tissue and blood cells • Autoimmunitytestingforcardiac patients

• Geneticcardiomyopathy

IKDT Innovative Diagnostics

•Geneexpressionstudies, microRNA profiling•Mitochondrialdisorders•Multiplexcytokineprofilingin peripheral blood•Measurement of phosphoproteins • SNPgenotypingbyQPCR& sequencing• Stemcellactivation&pluripotency screening• STRanalysisforsample

identification&puritytesting

Institut Kardiale Diagnostik und Therapie GmbHMoltkestr. 3112203 BerlinGERMANyT +49 (0) 3084 4155 40F +49 (0) 3084 4155 55info@ikdt.dewww.ikdt.dewww.innovative-diagnostics.eu

���������������������������������� ������

COMPETENCE & RELIABLE SERVICE – YOUR SERVICE PROVIDER FOR IN-VITRO DIAGNOSTICS

For over 10 years, our team consisting of highly qualified scientists has supported the development and quality assurance of in-vitro diagnostics worldwide due to its extensive knowledge, particularly in the area of autoimmunity and assay development.Here our competencies encompass the entire value-added chain of the company‘s products: from the supply of raw materials to protein biochemistry, order development and order production as well as the implementation of clinical studies.

Provision of serums / plasma / tissue / ... / Samples of human origin• Project-oriented,accordingtothehighestethicalstandards, extensive clinical documentation• High-qualitymaterialsandappropriatestorage• Large-scalesamplesandextensivestudygroups

Clinical studies / Enhanced biobanking• Assayvalidationandpre-marketing• Projectmanagementandcoordination• Consistencyandplausibilitytests

Protein biochemistry• Nativeantigens,antibodiesandspecificproteins• Variouslabelsandtheirmarkings• Qualitycontrolsinthein.ventdesignandOEM

Assay systems• Orderdevelopmentandorderproduction• Productionandpackaging• Quicktests,ELISAsandautomation

COMPETENCIES

Your ideas and our know-how

•Providingbiologicalrawmaterials

of human origins

•Proteinbiochemistry

•Orderdevelopment

•Clinicalstudies/Enhanced

biobanking

in.ventDIAGNOSTICAGmbHNeuendorfstraße1716761HennigsdorfGERMANYT+49(0)3302551991-2F+49(0)3302551991-0info@inventdiagnostica.dewww.inventdiagnostica.de

Highest possible qualityEthicallybeyondreproachCustomerandquality-oriented

SOFTWARE AND DEVELOPMENT DIVISION

This area focuses on the development of premium communication solutions which internetwork the out-patient and in-patient world of healthcare. Given this background, lab@ccess, a web-based lab or-der and finding communications system was developed. lab@ccess supports integrated patient care and creates a uniform perspective of findings. Due to its standardized interfaces, lab@ccess completely depends on hospital, lab and practice-oriented system manufactur-ers. The system solution creates a central communications platform and provides a lot of diverse information which supports data sha-ring with the lab and assessments of key business figures and thereby achieves cost transparency.

MOLECULAR MEDICINE DIVISION

Here our core competence is the development of rapid and high-quality verification systems to detect bacteria and viruses as well as the allele discrimination of hereditary diseases using cutting-edge methods in molecular biology. It is already possible to verify viral and bacterial infectious substances after several hours with the developed methods. So far, more than 30 methods have been developed. All products are marked with the CE certificate accor-ding to the IvD directive.

COMPETENCIES

Software and consultation

•Softwaredevelopment

•Systemintegration

•Processconsultation

•ITinfrastructureconsultation

Molecular medicine division

•Infectionserology

•Infectiondiagnostics

•Methodtoanalyzegeneticpre-

disposition

We are partners in the TERA-Diagnostik flagship project within the common innovation strategy of the states of Berlin and Brandenburg.

Limetec Biotechnologies GmbHLadeburger Straße 1716321 BernauGERMANYT +49 (0) 33 38 69 42 65F +49 (0) 30 80 50 51 75info@limetec-biotechnologies.dewww.limetec-biotechnologies.de

COMPETENCIES

Tailored solutions through comprehensive cross-sector experience – in collaboration with the customer and not just on his order.

It is my dedication to provide you as decision maker in the healthcare industry with consulting services that will ensure successful transformation of your products and projects into promising personalized medicine.

Personalized medicine is the intention of promising products in diagnostics and pharmacotherapy, partially already today and even more in the future. It goes along with highly complex and new requirements for strategic development and commerciali-zation of such therapeutic/diagnostic concepts. To meet these requirements a profound insight into the whole subject area and a wealth of experience in this promising fi eld is needed. Both of which I can offer to you extensively.

My consulting services cover the full spectrum of personalized medicine, from building the basic conceptual framework through product development to marketing strategies.

It is based on a wide range of activities which I implemented successfully over many years in various capacities in technology/diagnostics, drug development and commercialization – on a national as well as international level in various capacities.

It is the extensive practical experience that will deliver the best solutions for you. And additional competency & guarantee comes in through a network of experienced partners.

COMPETENCIES

Consulting services

• Strategic concept development

• Business Development support

• Project specifi c, scientifi c and

operational consultancy

• Building and assisting appropriate

partnerships

• Market access and

lifecyclemanagement

• Support in PR strategies

• Expert networks

Martina Kaufmann Strategic ConsultingDr. Martina KaufmannDorfmatt 2279379 MuellheimGERMANYT +49 (0) 76 31 74 86 52mk@mk-stracon.comwww.mk-stracon.com

MicroDiscovery develops software and quality-assured bioinfor-matics solutions in the areas of innovative diagnostics, biomedical research and personalized medicine. The portfolio also includes biostatistical data analysis and data management.

Efficient proprietary algorithms are the basis for customer-speci-fic software development for in-vitro diagnostics and biomedical technology. Areas of application are the classification and analysis of molecular and high-throughput data as well as image analyses and medical device control. Solutions can be developed as CE cer-tified, FDA compliant (21 CRF part 11) and ISO 62304 compliant. Software is programmed in Java, C++ (incl. Qt), GWT and the sta-tistical programs R and S.Moreover we offer service and support in bioinformatics and bio-statistics. MicroDiscovery has long-time experience in design, re-alization and evaluation of preclinical and clinical studies to find and validate biomarkers. This also includes the implementation of dedicated algorithms. In the fields of Genomics, Proteomics and Metabolomics MicroDiscovery provides data integration, databa-se development and data mining.

MicroDiscovery is DIN ISO 9001:2008 certified by TÜV Rheinland.

coMpetencies

Software development

•Customerspecified

OEM solutions

•Developmentofalgorithms

Data analysis and

Data management

•DataminingforNGSand

HTS data

•Dataintegrationanddatabase

development

Biostatistical analysis

•Evaluationofclinicaltrials

•Biomarkervalidation

We comply with the relevant standards: 98/79/EC, FDA CRF21 part 11, 2007/47/EC, ISO 13485, ISO 14971 and ISO 62304.

MicroDiscovery GmbHMarienburger Straße 110405 BerlinGERMANYT +49 (0) 30 44 350 90-0F +49 (0) 30 44 350 90-10 info@microdiscovery.dewww.microdiscovery.de

The company opTricon, headquartered in Berlin, is an OEM (Original Equipment Manufacturer) developing and producing Lateral Flow Reader for the quantitative analysis of immunological rapid tests, so-called Lateral Flow Assays (LFAs). These are used in cancer and heart attack detection, the diagnosis of allergies, and other medical areas, but also in the analysis of agricultural products and the environment. The universal device platform opTrilyzer®, developed specifically for this purpose, can be applied to all the usual test strip formats that require high-resolution measurement in the case of a low concentra-tion of analytes.

The innovative core of the device is the camera with its two-dimensio-nal CCD image sensor, which does not only scan the test strip line-by-line as in the usual systems, but rather records a complete image of the test strip. The picture quality is therefore of a much higher quality allowing an optimal evaluation of the test results.

The devices are individually configured for the corresponding LFA test in close cooperation with our customers. User-friendly configu-ration and data management software is also provided. The device itself has an appealing intuitive interface and compact design, which makes its use in on-the-go situations particularly comfortable and simple. A connection to Hospital Information Systems in order to ma-nage data and test results is also possible.

As opTrilyzer® Med Plus and opTrilyzer® Med Fluo the device can be adapted to use on test cartridges with multiple LFA test strips as well as fluorescence-based tests.

compeTencies

• Lateral Flow Reader

•Universalmobilereadersystem

•Medicaldiagnostics

•Foodanalytics

•Analyticsofagriculturalproducts

•Environmentalanalytics

•Reliablequantitativeevaluation

•Color-change-basedLFAtests

•Fluorescence-basedtests

•Testswithmultipleteststrips

•Highmeasurementstandards

•User-friendlyinterface

•Individualcustomizing

opTricon Entwicklungsgesellschaft für optische Technologien mbH Schwarzschildstraße 112489 Berlin GERMANYT +49 (0) 30 63 92 20-32F +49 (0) 30 63 92 20-37info@optricon.dewww.optricon.de

PolyAn GmbH – moleculAr SurfAce enGineerinG

PolyAn is a nanotechnology company specialized in the modification of sur-faces using Molecular Surface Engineering (MSE). PolyAn develops and pro-duces functionalized consumables for molecular diagnostics and life science research. Customers include well-known diagnostic companies, providers of analytic systems for agricultural and environmental applications as well as re-search organizations for biomarker and pharmaceutical screening.

Multiplex systems play an increasingly important role in the rapidly growing world market for molecular diagnostics. The simultaneous measurement of multiple biomarkers can improve both sensitivity and specificity as well as reduce costs. However, considering such applications the consumables’ surface becomes increasingly vital for the performance: because decrea-sing sample volumes often aggravate unspecific interactions with the sur-face while low biomarker concentrations cause insufficient test sensitivity.

In order to address these problems in molecular diagnostics applications PolyAn has developed two product families for the most widespread con-sumable formats such as slides, 96-well plates and microparticles which are functionalized using Molecular Surface Engineering. Features of PolyAn’s MSE technology are: a) the covalent anchoring of a specific nanoporous 3D-functional matrix on the surface of organic and inorganic compounds, b) the incorporation of antifouling matrices which reduce non-specific bin-ding and thus enable optimal signal-to-noise ratios and c) the variation of the surface morphology.The combination of surface morphology and selection of functional (che-mical) groups in PolyAn’s tightly controllable functionalization process ena-bles fine-tuning both hydrophilicity and density of functional groups for specific coupling within a specified narrow range.

comPetencieS

Functionalized Microarray Slides

plastic or glass slides as well as functio-

nalized 96-well plates for DNA, peptide

or protein microarrays with medium to

high density

Microparticles

2–25 µm monodisperse, fluorescence en-

coded PMMA-Beads, e.g. for multiplex

bead assays or calibration of cell assays

Molecular Surface Engineering

In addition to slides and beads, PolyAn

offers consumable and substrate ma-

terials for OEM applications which are

tailored to the customer’s requirements.

They include highly robust wicking ma-

terials for sensor applications, sample

vessels equipped with antifouling layers

for cell analytics and reactive substrates

for solid phase synthesis of complex

molecules. Additionally, PolyAn provi-

des calibration systems for fluorescence

based detection systems.

PolyAn GmbHRudolf-Baschant-Str. 213086 BerlinGERMANYT +49 (0) 3091 2078-0F +49 (0) 3091 2078-11mail@poly-an.dewww.poly-an.de

Predemtec GmbH focuses on research, development, manufacturing and marketing of novel immunoassays to assess risk factors of demen-tia. Predemtec conducts early and risk diagnosis of Alzheimer’s disease (AD) using blood samples. For the fi rst time, this non-invasive blood test allows to identify risk factors of dementia early and reliably. It is cer-tain that AD starts 10 to 15 years before the fi rst clinical signs become apparent and that compensating mechanisms of the central nervous system (CNS) counterbalance pathological processes: one reason why dementia stays unnoticed for a long time. In this – clinically unappa-rent – stage processes take place that are characterized by biomarkers enabling to initiate disease-modifying treatments: both preventive and biomarker specifi c therapies (M.T. Heneka, Nervenarzt 2010).

However, clinicians still diagnose dementia much too late meaning that they can undertake only few preventive and therapeutic actions – due to the immense time delay. But now, assays developed by Predemtec support establishing new therapies.

The Predemtec GmbH cooperates with the Institute of Immunology at the University of Kiel, the Memoryclinic Basel and various neurological and geriatric clinics in Germany and Switzerland. As a member of the diagnostic network Predemtec is able to offer services for early demen-tia diagnosis for clinics and laboratories.

COMPETENCIES

• Production and distribution of

biomarkers for early diagnostics

of dementia

• Neurobiological consulting for

early diagnostics of dementia

• Development of innovative

assays to detect dementia at an

early stage

Predemtec GmbHDemenz-Diagnostik und Beratung Neuendorfstrasse 20a16761 HennigsdorfGERMANYT +49 (0) 3302 202 1600info@predemtecdx.comwww.predemtecdx.com

ß Dr. Annegret Feuerhelm-Heidl founder and managing director

COMPETENCIES

ß High throughput biochip production with sciFLEXARRAYER S100

SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research.

The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of valuable and sensitive compounds of biological or chemical origin. SCIENION dispen-sers allow for contact-free and precise spotting in the pico- to microliter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. SCIENION provides fl exible solutions for research and development and customized solutions for production pur-poses. Systems and software are characterized by their versatility, precision and robustness.

Based on a strong background in miniaturization and multi-plexing technologies, SCIENION offers extensive and all-round microarray development services and manufacturing of different types of high quality microarrays for IVD and R&D applications. Our validated technology and complete liquid handling portfo-lio, in combination with our scientifi c knowledge and experience, fulfi ll your specifi c needs for high quality and high performance tests and systems.

SCIENION AG is certifi ed according to DIN EN ISO 9001:2008 for the development, manufacture, and sales of dispensing sys-tems and microarrays.

COMPETENCIES

Miniaturization and Development of

Multiplex Assays

• Glycan-, DNA-, protein-, peptide

microarrays, miniaturized ELISAs,

biosensors loading, miniaturized

PCR, toxicity assays

Instruments and Services

• sciFLEXARRAYER

dispenser/spotter for biological

and chemical agents

• Proprietary piezo- and nanoliter

dispensing technology

• Surface functionalization 2D / 3D

• Customized solutions: from R&D

to ISO-certifi ed high throughput

production

• Contract development and

production of in-vitro diagnostics

Consumables

• Functionalized microtiter plates

• Coated slides and buffer for high

quality microarrays

SCIENION AGVolmerstr. 7b12489 BerlinGERMANYT +49 (0) 30 6392 1700F +49 (0) 30 6392 1701support@scienion.comwww.scienion.com

The roots of SIFIN GmbH Berlin, founded in 1991, date back to the early 19th century. Under Bismarck it bore the name ‘Berliner Impfanstalt’ (Berlin Institute for Vaccinations) and became part of the ‘Institut für Seuchenschutz’ (Institute for the Control of Epide-mics), which in 1966 became known as the ‘Staatliches Institut für Immunpräparate und Nährmedien’ (State Institute for Immunopre-parations and Culture Media). In 1992, with the help of a private investor, the diagnostic divisions continued running and were de-veloped successfully.

• Bacteriological test reagents for use in serotyping of Salmonella, Shigella, E. coli and Yersinia: Especially for the diagnosis of Sal- monella we have switched a substantial part of the range of ag- glutinating reagents from polyclonal to monoclonal antibodies.

• Culture media and supplements for detection of microorganisms: We provide more than 250 different culture media and supple- ments in order to culture the microorganisms you are looking for. Thus, you are optimally equipped for analysis of food, water, pharmaceutical products, cosmetics as well as veterinary samples.

• Blood grouping serological products: Serafol® bedside cards for identity check, test reagents for blood determination and test reagents, kits or containers for the PK® system.

• Monoclonal antibodies: SIFIN offers contract manufacturing of monoclonal antibodies based on your cell line. Benefit from our many years of experience in contract manufacturing of mono- clonal antibodies

CoMpEtENCIES

Monoclonal antibodies for diagnostics

•Manufacturing•Purification•OEMbulkproduction•Cellbanking•Cloning•Specialities

Development, manufacturing and

distribution

•Testreagentsformicrobiology and immunochemistry•Testreagents,kitsandcontainers for blood determination•Serafol®bedsidecards•Ready-to-useanddehydrated culture media •Contractmanufacturing

ßMonoclonal antibodies for diagnostics

Certified quality management system:DINENISO9001•DINENISO13485•FDAappro-ved•Manufacturingpermitforveterinarydiagnosticmonoclonalantibodies•FDAapprovedcGMPproductionsiteformonoclonalantibodiessince2004•IVDdirective98/79/EC–listAproducts

SIFIN Institut für Immunpräparate undNährmedienGmbHBerlinBerlinerAllee317–32113088BerlinGERMANYT+49(0)30927030-0F+49(0)30927030-30info@sifin.dewww.sifin.de

Thermo Scientific B·R·A·H·M·S Biomarkers investigates, develops and manufactures novel diagnostic test procedures to improve early diagnosis and treatment of life-threatening diseases. With our high-quality immunodiagnostic tests for sepsis, cardiovascular, pulmonary, and cancer disorders as well as prenatal screening we contribute to the creation of a healthier future – to the greatest advantage for me-dical professionals and patients.

In the future simple and economic blood tests will be of great im-portance for an early detection and successful treatment of diseases. Taken together our know-how and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 65 countries worldwide and support them in making clinically and economically superior decisions.

On the basis of our completely owned patents and with the help of more than 470 employees worldwide Thermo Scientific B·R·A·H·M·S Biomarkers is a leading company in specific market places and the-rapeutic areas.

coMpeTencieS

Therapeutic Areas

• Infections

•Cardiovasculardiseases

•Pulmonarydiseases

•Thyoroiddiseases

•Tumordiseases

•Prenatalscreening

Technologies

•FullyautomatedKRYPTORplat-

formwithTRACEtechnology

•Radioimmunoassays

•Luminescenceassays

•Enzymeimmunoassays

The aim of our basic research is to

identify new biomarkers, supported

by international cooperations and

reputable research institutions.

Thermo Fisher ScientificNeuendorfstraße 2516761 HennigsdorfGERMANYT +49 (0) 3302 883-0F +49 (0) 3302 883-100info.brahms@thermofisher.comwww.thermoscientific.com/brahms

ß Main building and entrance of Thermo Fisher Scientific in Hennigsdorf (north of Berlin)

The research at the department for biosystems technology focu-ses on the electrochemical behavior of biomolecules on metal and carbon electrodes. Furthermore we are interested in methods to determine the binding properties of biomolecules, especially with respect to their interaction on modified surfaces. Our main goal is the development of new biosensors to detect radicals, meta-bolites, toxins, viruses, bacteria, DNA and antibodies. The sensor-design uses different approaches e.g. self-organizing processes, polymer inclusions, covalent coupling and in particular the const-ruction of multi-layer architectures on electrode-surfaces. A further focus is on the synthesis and modification of new nanomaterials (e.g. quantum dots, metal- and silica-nanoparticles, carbon-nano-tubes) and its combination with biomolecules. The laboratory equipment allows state-of-the-art analysis of bio-molecular systems. This includes a broad spectrum of methods to measure binding properties such as QCM, SPR spectroscopy as well as spectroscopic techniques for the detection of structural changes and electrochemical approaches to investigate electron transfer. Furthermore several techniques for surface modification and characterization, e.g. nano-lithography, spin coating, ellipso-metry, SEM and AFM have been established.

competencies

Methods

•Electrochemicalapproaches(EIS;

voltammetry)

•Bindingcharacterization(QCM/

QCMD/SPR,IEF)

•Spectroscopy(UV-Vis;fluores-

cence;f.-polarisation,FT-IR)

•Surface modification (nano-litho-

graphy,plasma,e-spinning;a.s.o.)

•Surface characterization (ellipso-

metrie;contactangle,SEM;AFM)

•Particle characterization (dynamic-

light scattering, zeta potential)

Topics

•Biosensors

•Redoxproteins

•Nanoparticlesynthesis

•Enzymaticsystems

•DNAundaptamers

•Antibodycharacterization

Technische Hochschule Wildau(UniversityofAppliedSciences)BiosystemsTechnologyProf. Dr. rer. nat. habil. F. LisdatBahnhofstrasse115745WildauGERMANYT+49(0)3375508456799F+49(0)3375508458flisdat@th-willdau.dewww.th-wildau.de/lisdatwww.brandenburg-invest.dewww.capital-region.de

Our expertise is the development of new diagnostic and bioana-lytical methods for medical diagnostics and environmental & food control and the investigation of underlying processes.

Our research activities cover the development of new analyte spe-cific recognition elements like antibody fragments, recombinant enzymes and biomimetic polymers, their (electronic) coupling to transducers, biosensor and bioassay development mainly on the basis of fluorescence and electrochemical signal generation. For detection of very low target concentrations e.g. for metabolites, nucleic acids, proteins or pesticides a panel of biochemical sig-nal amplification principles have been created over the last years. Various devices and methods are available for characterization of sensor surfaces and for determination of kinetic constants of the recognition processes.

Within the last six years three BMBF Innoprofile research groups have been established dealing with the development of new bio-chips for point-of-care diagnostics, laser-based analytical methods and new methods for antibody generation. Furthermore we are partner in the Excellenzcluster Unicat and in several integrated re-search projects directed to next-generation autonomous biosen-sors.

competencies

Biorecognition elements, Proteins

and Bioassays

•Proteinexpression

•Antibodyandenzyme

engineering

•Chemicalbioconjugatesynthesis

•Enzymaticassays

•AntibodyassaysandELISA

•Biochemicalamplificationme-

thods for highly sensitive assays

Biosensors and Biochips

•Opticalandelectrochemical

methods

•Immobilizationofbiomolecules

•Antibodychips

•Enzymesensors

•Proteinchipsforpoint-of-care

diagnostics

•Lab-on-a-chip

ßSchemeofaproteinchipfor point-of-care diagnostics

University of PotsdamDr.habil.AxelWarsinkec/o Fraunhofer IBMTAmMühlenberg1314476Potsdam,GolmGERMANYT+49(0)033158187-561F+49(0)033158187-562warsinke@uni-potsdam.dewww.uni-potsdam.de

The ZukunftsAgentur Brandenburg GmbH (ZAB) is the single point of contact with the state of Brandenburg for investors, regi-onal businesses and technology-oriented business start-ups. The ZAB service profile includes both business development and sup-port programs for innovation, technology and export as well as an energy consultation service and support for technology transfer and business networks. ZAB currently coordinates and supports 18 GRW networks as part of a joint scheme to improve the regional economic structure.

The ZAB is the Energy Efficiency Agency for the state of Branden-burg and offers businesses and communities comprehensive and expert advice on energy issues. The ZAB works closely with the Investment Bank of the state of Brandenburg (ILB) and BC Bran-denburg Capital GmbH. This enables the ZAB to provide detailed advice about state, federal and EU funding as well as financing options.

With its central office in Potsdam and five regional centers, it can provide onsite consultation services throughout the entire sta-te. Together with Berlin Partner GmbH, the ZAB markets Berlin-Brandenburg as a hub of business and technology and shares a joint office for the development of the area around the new Berlin Brandenburg airport in Schönefeld. Together with the technology foundation Innovationsagentur Berlin GmbH, ZAB has a joint acti-vity agreement for an innovation strategy. There are close relation-ships amongst the university and research community of the state of Brandenburg – for example, through the patent exploitation agency Brainshell.

competencies

•Consultativeknow-howforhigh

growth future industries

•Supportforregionalbusinesses

in Brandenburg

•Tradefairs,businesstravel,events

as well as the utilisation of EU

funding programs, international

technology transfer and partici-

pation in the 7th Research

Framework Programme

ZukunftsAgentur Brandenburg GmbHSteinstraße 104–10614480 PotsdamGERMANYT +49 (0) 331 660 30-00F +49 (0) 331 660 38-40info@zab-brandenburg.dewww.zab-brandenburg.dewww.brandenburg-invest.dewww.capital-region.de

DNA SCITSONGAID ROF SECIVRES DNA STCUDORPERA EW OHWRESEARCH

DiagnostikNet | BB is a high-performance network of

Diagnostics from one source: DiagnostikNet | BB offers a wide range of high-quality services and products.

| kitsongaiD | smadA ekuarF .rD Net BB | Netzwerk Diagnostik Berlin-Brandenburg e.V.Neuendorfstrasse 17 | 16761 Hennigsdorf | Germany

T +49 (0) 3302 551 99-14 | F +49 (0) 3302 551 99-10 | M +49 (0) 172 162 31 88f.adams@diagnostiknet-bb.de | www.diagnostiknet-bb.de

• diagnostics providers• device manufacturers• leading research institutes• clinics and medical laboratories• expert partners

YOU PROFIT FROM

• the combination of expertise of our network members• our access to new technologies• flexible and short decision-making processes allowing us to implement diagnostic solutions quickly and efficiently• one contact person as general contractor to manage all your specific requests• the organizational stability of an established consortium

• supply of biological raw materials | biobanking

• biomarker finding, development, and validation

• design and execution of clinical diagnostic trials

• platform-independent assay development

• companion diagnostics

• devices | detection systems | biosensors

• lab-on-the-chip | custom expression arrays

• point-of-care testing | multiparameter bioassays

• data management | bioinformatics

• laboratory automation

• software | wireless and broadband communications

• certification | accreditation

• services in molecular diagnostics and clinical chemistry

• CE mark | FDA approval | OEM production

in the Berlin-Brandenburg region. Together we develop and manufacture innovative in-vitro diagnostic solutions.

The network covers the complete value-added chain of in-vitro diagnostics. Each of our network partners has extensive knowledge and long-standing expertise in its special field. For this reason, we are able to offer you a broad range of high-quality services and products from prevention and early detec--tion to diagnostics, therapy monitoring and ongoing care.

The area of veterinary medicine, food, agriculture, and environment are secondary to clinical diagnostics and research examples for further fields of application.

Pool of suitable partners

BERLINBRANDENBURG

BEBEBEEBEBEBERLINBRANDENBNBBBUUURG

t| BB

Customers

Productsof network partners

Consortium

etwork partne

Support by the network

management